Advanced BioMedical Technologies, Inc.: 10-Q filed 2020-06-22
What Advanced BioMedical Technologies, Inc. reported in its quarterly report filed 2020-06-22 (fiscal Q2 2020): 36 published measures, 100 facts as tagged in accession 0001493152-20-011580.
This filing
- Form
- 10-Q (quarterly report)
- Filed
- 2020-06-22
- Fiscal period
- fiscal Q2 2020
- Accession
- 0001493152-20-011580 on SEC EDGAR
Values are as tagged in this filing. A later filing can restate them; a measure with a published history links to it, and the history shows the latest-filed value per period. All Advanced BioMedical Technologies, Inc. filings.
Reported measures
Total assets
Resources recognized on the balance sheet. Book assets are not the market value of the business.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2020-04-30 | 276,357 | USD | |
| At 2019-10-31 | 218,500 | USD |
Stockholders equity
The reported residual interest after liabilities. It is an accounting amount, not market capitalization.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2020-04-30 | -6,720,049 | USD | |
| At 2020-01-31 | -6,641,855 | USD | |
| At 2019-10-31 | -6,478,239 | USD | |
| At 2019-04-30 | -6,280,518 | USD | |
| At 2019-01-31 | -6,080,031 | USD | |
| At 2018-10-31 | -5,619,012 | USD |
Cash and cash equivalents
Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2020-04-30 | 10,640 | USD | |
| At 2019-10-31 | 5,592 | USD |
Net income or loss
Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2020-02-01 to 2020-04-30 | -209,652 | USD | 90 |
| 2019-11-01 to 2020-04-30 | -273,441 | USD | 182 |
| 2019-11-01 to 2020-01-31 | -63,789 | USD | 92 |
| 2019-02-01 to 2019-04-30 | -235,679 | USD | 89 |
| 2018-11-01 to 2019-04-30 | -488,202 | USD | 181 |
| 2018-11-01 to 2019-01-31 | -252,523 | USD | 92 |
Operating cash flow
Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2019-11-01 to 2020-04-30 | -206,897 | USD | 182 |
| 2018-11-01 to 2019-04-30 | -428,039 | USD | 181 |
Capital expenditure payments
Cash payments to acquire property, plant and equipment. This taxonomy concept does not capture every form of investment or acquisition.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2019-11-01 to 2020-04-30 | 28,270 | USD | 182 |
| 2018-11-01 to 2019-04-30 | 12,099 | USD | 181 |
Contract revenue excluding tax
Revenue from customer contracts excluding assessed taxes under this specific taxonomy concept. It is not automatically comparable to older revenue tags.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2020-02-01 to 2020-04-30 | -211 | USD | 90 |
| 2019-11-01 to 2020-04-30 | 60,290 | USD | 182 |
Financing cash flow
Net cash from financing activities, including borrowing, repayments and transactions with owners. A positive amount does not establish operating profitability.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2019-11-01 to 2020-04-30 | 240,265 | USD | 182 |
| 2018-11-01 to 2019-04-30 | 462,313 | USD | 181 |
Investing cash flow
Net cash from investing activities, including asset purchases, disposals and investment transactions. This differs from capital expenditure payments alone.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2019-11-01 to 2020-04-30 | -28,270 | USD | 182 |
| 2018-11-01 to 2019-04-30 | -29,364 | USD | 181 |
Retained earnings or deficit
Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2020-04-30 | -9,857,805 | USD | |
| At 2019-10-31 | -9,581,438 | USD |
Basic weighted-average shares
Time-weighted shares used for basic earnings per share. This denominator differs from shares outstanding at a single reporting date.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2020-02-01 to 2020-04-30 | 69,940,406 | shares | 90 |
| 2019-11-01 to 2020-04-30 | 69,907,268 | shares | 182 |
| 2019-02-01 to 2019-04-30 | 69,624,850 | shares | 89 |
| 2018-11-01 to 2019-04-30 | 69,624,850 | shares | 181 |
Diluted weighted-average shares
Weighted-average shares used for diluted earnings per share. Potential shares are included under the applicable dilution rules, not simply added to outstanding shares.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2020-02-01 to 2020-04-30 | 70,097,739 | shares | 90 |
| 2019-11-01 to 2020-04-30 | 69,985,070 | shares | 182 |
| 2019-02-01 to 2019-04-30 | 69,624,850 | shares | 89 |
| 2018-11-01 to 2019-04-30 | 69,624,850 | shares | 181 |
Net property, plant and equipment
Carrying amount of property, plant and equipment after accumulated depreciation, depletion and amortization. It is not replacement cost or market value.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2020-04-30 | 112,321 | USD | |
| At 2019-10-31 | 99,034 | USD |
Share-based compensation expense
Reported noncash expense for share-based payment arrangements. Noncash treatment does not mean the awards have no economic cost to shareholders.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2020-02-01 to 2020-04-30 | 6,467 | USD | 90 |
| 2019-11-01 to 2020-04-30 | 6,467 | USD | 182 |
Operating income or loss
Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2020-02-01 to 2020-04-30 | -120,334 | USD | 90 |
| 2019-11-01 to 2020-04-30 | -219,979 | USD | 182 |
| 2019-02-01 to 2019-04-30 | -148,528 | USD | 89 |
| 2018-11-01 to 2019-04-30 | -318,437 | USD | 181 |
Current assets
Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2020-04-30 | 111,553 | USD | |
| At 2019-10-31 | 119,466 | USD |
Current liabilities
Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2020-04-30 | 6,983,314 | USD | |
| At 2019-10-31 | 6,696,739 | USD |
Operating expenses
Recurring operating costs under this accounting concept, generally excluding production costs included in cost of sales. Check filing presentation before combining expense subtotals.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2020-02-01 to 2020-04-30 | 120,239 | USD | 90 |
| 2019-11-01 to 2020-04-30 | 247,258 | USD | 182 |
| 2019-02-01 to 2019-04-30 | 148,528 | USD | 89 |
| 2018-11-01 to 2019-04-30 | 318,437 | USD | 181 |
Net inventory
Inventory carrying amount after applicable valuation and LIFO reserves. It does not establish realizable selling proceeds or inventory turnover without other inputs.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2020-04-30 | 64,509 | USD | |
| At 2019-10-31 | 64,107 | USD |
Gross profit
Revenue less the costs directly attributed to the goods or services sold. It precedes other operating expenses and is not net income.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2020-02-01 to 2020-04-30 | -95 | USD | 90 |
| 2019-11-01 to 2020-04-30 | 27,279 | USD | 182 |
Research and development expense
Research and development costs recognized as expense. Capitalization policies and acquired projects can make this differ from total cash invested in development.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2020-02-01 to 2020-04-30 | 41,305 | USD | 90 |
| 2019-11-01 to 2020-04-30 | 98,085 | USD | 182 |
| 2019-02-01 to 2019-04-30 | 16,043 | USD | 89 |
| 2018-11-01 to 2019-04-30 | 33,022 | USD | 181 |
Common shares outstanding
Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2020-04-30 | 69,974,850 | shares | |
| At 2019-10-31 | 69,874,850 | shares |
Accumulated other comprehensive income or loss
Cumulative other comprehensive items after tax, such as translation and unrealized hedging or securities effects. These amounts have not passed through net income.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2020-04-30 | 355,657 | USD | |
| At 2019-10-31 | 334,363 | USD |
Operating lease right-of-use asset
Carrying amount of the right to use leased assets under operating leases. It reflects discounted remaining payments, not the value of the underlying property.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2020-04-30 | 52,483 | USD |
Operating lease liability
Present value of remaining operating lease payments. Discount-rate choices and lease terms affect the amount; it is not the sum of undiscounted future rent.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2020-04-30 | 55,390 | USD |
Gross property, plant and equipment
Cost of property, plant and equipment before accumulated depreciation. Historical cost does not indicate current value or replacement cost.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2020-04-30 | 560,922 | USD | |
| At 2019-10-31 | 534,666 | USD |
Accumulated depreciation on property, plant and equipment
Cumulative depreciation, depletion and amortization recorded against property, plant and equipment. It measures cost allocation to date, not physical wear or market value.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2020-04-30 | 448,601 | USD | |
| At 2019-10-31 | 435,632 | USD |
Prepaid expenses and other current assets
Prepayments and other current assets grouped under this concept. The balance is not cash and its composition differs by filer.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2020-04-30 | 36,404 | USD | |
| At 2019-10-31 | 49,767 | USD |
Pre-tax income or loss from continuing operations
Income or loss from continuing operations before income taxes and noncontrolling interests. It excludes discontinued operations and is not net income.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2020-02-01 to 2020-04-30 | -209,652 | USD | 90 |
| 2019-11-01 to 2020-04-30 | -273,441 | USD | 182 |
| 2019-02-01 to 2019-04-30 | -235,679 | USD | 89 |
| 2018-11-01 to 2019-04-30 | -488,202 | USD | 181 |
Profit or loss including noncontrolling interests
Net income or loss including the portion attributable to noncontrolling interests. It can differ from the net income attributable to the parent that per-share figures use.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2020-02-01 to 2020-04-30 | -209,652 | USD | 90 |
| 2019-11-01 to 2020-04-30 | -273,441 | USD | 182 |
| 2019-02-01 to 2019-04-30 | -235,679 | USD | 89 |
| 2018-11-01 to 2019-04-30 | -488,202 | USD | 181 |
Comprehensive income or loss
Net income plus other comprehensive income after tax. It includes unrealized items that net income excludes and is not a cash measure.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2020-02-01 to 2020-04-30 | -88,068 | USD | 90 |
| 2019-11-01 to 2020-04-30 | -252,147 | USD | 182 |
| 2019-02-01 to 2019-04-30 | -203,694 | USD | 89 |
| 2018-11-01 to 2019-04-30 | -667,861 | USD | 181 |
General and administrative expense
General and administrative costs reported under this concept, separate from selling expense. Filers group overhead differently, so compare presentation before comparing companies.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2020-02-01 to 2020-04-30 | 57,776 | USD | 90 |
| 2019-11-01 to 2020-04-30 | 112,061 | USD | 182 |
| 2019-02-01 to 2019-04-30 | 127,472 | USD | 89 |
| 2018-11-01 to 2019-04-30 | 275,402 | USD | 181 |
Depreciation expense
Depreciation recognized for the period under this concept. It is a noncash allocation of asset cost and may exclude amortization and depletion reported elsewhere.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2020-02-01 to 2020-04-30 | 3,944 | USD | 90 |
| 2019-11-01 to 2020-04-30 | 9,076 | USD | 182 |
| 2019-02-01 to 2019-04-30 | 5,013 | USD | 89 |
| 2018-11-01 to 2019-04-30 | 10,013 | USD | 181 |
Nonoperating income or expense
Total nonoperating income or expense, which can include interest, investment results and other items. A positive value is not operating profit.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2020-02-01 to 2020-04-30 | -89,318 | USD | 90 |
| 2019-11-01 to 2020-04-30 | -53,462 | USD | 182 |
| 2019-02-01 to 2019-04-30 | -87,151 | USD | 89 |
| 2018-11-01 to 2019-04-30 | -169,765 | USD | 181 |
Interest paid, net
Cash interest paid during the period, net of amounts capitalized where the filer reports it that way. It differs from interest expense recognized.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2019-11-01 to 2020-04-30 | 10 | USD | 182 |
| 2018-11-01 to 2019-04-30 | 17 | USD | 181 |
Change in inventories
The cash flow adjustment for the change in inventories during the period. A positive value under this concept means inventory grew and reduced operating cash flow.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2019-11-01 to 2020-04-30 | 627 | USD | 182 |
| 2018-11-01 to 2019-04-30 | 13,999 | USD | 181 |
Inspect the source
- Entity
- Advanced BioMedical Technologies, Inc. / CIK 0001385799
- Captured
- SEC response SHA-256
1591f8b0cfab5a80255c1912235608d48fec8b1551b4e091e75b1bc63071e992
Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON
Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.
Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.
Use this in research
A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.
These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.
Research methodology · Execution and cost assumptions · Check backtest overfitting
Build with the open-source tools
Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.
- Get an API key and run your first validation
- Connect the MCP server to your coding assistant
- Inspect the ALPHAC engine on GitHub
- Read the MCP server source and integration examples
Read the published dataset with Python
import json
from urllib.request import urlopen
with urlopen("https://canlicapital.com/company-data/0001385799.json") as response:
record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
print(concept["tag"], next(iter(concept["observations"])))